CV Therapeutics touts heart-imaging drug's Phase III data

Palo Alto, California-based CV Therapeutics announced that its heart-imaging drug met the primary endpoint in a Phase III pivotal trial. Regadenoson is intended to increase blood flow and dilate coronary arteries so that a scan will reveal any threatening blockages and restrictions. Many patients increase their blood flow for the procedure with exercise, but a large group are physically incapable of doing it. The trial compared Regadenoson to Adenoscan from Astellas, which is partnered with CV on developing Regadenoson. A second Phase III trial is currently underway.

- read this story from the San Francisco Business Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.